An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors
Clinical trial NCT07774611 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07774611
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-09-22
- Primary completion
- 2028-06-30
- Enrollment
- 180
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.